Ralinepag Reduces PAH Patients’ Risk of Death, Phase 2 Trial Shows

  • This topic has 1 voice and 0 replies.
Viewing 0 reply threads
  • Author
    • #11402

      Arena Pharmaceuticals’ ralinepag reduced the risk of pulmonary arterial hypertension patients dying, a Phase 2 clinical trial showed.

      Temple University Professor Raymond Benza will present the results at the International Society for Heart and Lung Transplantation meeting in Nice, France, on April 14.  The four-day conference started April 11.

      The title of Benza’s presentation is “Ralinepag, An Oral, Selective, Prostacyclin (IP) Receptor Agonist Consistently Improved Mortality Risk Scores Derived From PAH Registries Across Three Regions: Phase 2 Study Analysis.” In addition to working at Temple, he is chair of cardiovascular research at Allegheny General Hospital in Pittsburgh.

      Ralinepag (APD811) is a selective prostacyclin receptor agonist. Prostacyclin is a substance produced by cells lining the walls of arteries and veins.It is a potent vasodilator, widening blood vessels so that blood flows better through them. It also inhibits platelet clumping and the growth of blood vessel muscle cells.

      The therapy stays in the body for some time, increasing its effectiveness.

      Read more about it here: “Ralinepag Reduces PAH Patients’ Risk of Death, Phase 2 Trial Shows

      What do you think about these news? Share your thoughts below.

Viewing 0 reply threads
  • You must be logged in to reply to this topic.

©2022 KLEO Template a premium and multipurpose theme from Seventh Queen


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials


Forgot your details?

Create Account

Verify you are not a robot